Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2008
-
By Donald Zuhn — Last November, on the heels of the Eastern District of Virginia’s decision to preliminarily enjoin the new continuation and claims rules, we offered a number of proposals that might help remedy the problems facing the U.S. Patent and Trademark Office. Among our proposed alternatives to the Patent Office’s draconian…
-
By Kevin E. Noonan — Once recombinant cells were deemed to constitute patentable subject matter by the U.S. Supreme Court in Diamond v. Chakrabarty, fundamental properties of such cells began to pose new challenges to traditional patent law concepts. One such property is that these cells were capable of replicating to produce copies…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Astrazeneca Pharmaceuticals LP et al. v. Mylan Pharmaceuticals Inc.1:07-cv-00177; filed December 28, 2007 in the Northern District of West Virginia Astrazeneca Pharmaceuticals…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Aventis Pharma S.A. et al. v. Hospira, Inc.2:07-cv-08137; filed December 14, 2007 in the Central District of California Infringement of U.S. Patent…
-
By Kwame Mensah — Last November, Cyplasin Biomedical Ltd. announced that it had been granted U.S. Patent No. 7,271,242, entitled "Cytotoxic Cyplasin of the SeaHare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants." The ‘242 patent covers the production of cytotoxic cyplasin by mammalian cells and the use of this protein for…
-
January 9, 2008 – Patent Claim Construction (Law Seminars International) – San Francisco, CA January 14-15, 2008 – Patent Law Institute (Practising Law Institute) – New York, NY January 25-26, 2008 – Buying, Selling and Licensing Patents: New Case Law, Rules, Legislation and Markets (Law Seminars International) – San Francisco, CA January 28-29, 2008 –…
-
By Christopher P. Singer — IpAuctions, Inc. has announced that it will be holding a ten day auction of intellectual property relating to bioscience and medical technologies from February 26 to March 5, 2008. The online auction firm is targeting general IP and patents particularly in the fields of cancer therapeutics and diagnostics,…
-
By Donald Zuhn — Last month, stART Licensing, Inc. announced that it had been granted U.S. Patent Nos. 7,304,204 and 7,307,198. stART Licensing, Inc., an Austin, Texas-based joint venture between Geron Corp. and Exeter Life Sciences, Inc., manages and licenses a portfolio of patent rights related to animal reproductive technologies (including patents encompassing…
-
By Donald Zuhn — On December 21, 2007, Illumina, Inc. announced that the U.S. Patent and Trademark Office had ordered the reexamination of U.S. Patent Nos. 6,355,432; 6,646,243; 5,545,531; and 5,795,716. The patents ordered into reexamination constitute four of the five patents that Affymetrix, Inc. asserted against Illumina in an infringement action filed…
-
By Donald Zuhn — Yesterday, we counted down stories #10 to #6 of the top stories covered at Patent Docs in 2007, and on Sunday, we listed stories #11 to #15. Today, we conclude the series by counting down the top five stories. In case you missed the articles the first time around…
Patent Docs 